Novartis Sues Apotex To Block Generic Exelon
Novartis AG has slapped Apotex Inc. with a patent infringement lawsuit in an effort to keep the Toronto-based drugmaker from introducing a generic version of the dementia treatment Exelon....To view the full article, register now.
Already a subscriber? Click here to view full article